Haemonetics Q4 EPS of $1.29 Beats Estimates, Up 4% Year-over-Year
HAE•Haemonetics generated fiscal fourth-quarter adjusted earnings of $1.29 per share, beating the consensus estimate by $0.01 and up 4% from $1.24 a year earlier. The company also reported revenue growth that surpassed analyst forecasts for the quarter.
1. Q4 Earnings Beat
Haemonetics reported adjusted EPS of $1.29 for fiscal fourth quarter, surpassing the consensus estimate of $1.28 per share by $0.01.
2. Year-over-Year Growth
The $1.29 per share represents a 4% increase compared with $1.24 in the fourth quarter of the prior year, driven by improved operational efficiencies.
3. Revenue Performance
Total revenue for the quarter exceeded analyst forecasts, reflecting strong demand across the company’s blood management and diagnostic technologies business lines.
